400 related articles for article (PubMed ID: 22065400)
1. A randomized, crossover, placebo- and moxifloxacin-controlled study to evaluate the effects of bosutinib (SKI-606), a dual Src/Abl tyrosine kinase inhibitor, on cardiac repolarization in healthy adult subjects.
Abbas R; Hug BA; Leister C; Sonnichsen D
Int J Cancer; 2012 Aug; 131(3):E304-11. PubMed ID: 22065400
[TBL] [Abstract][Full Text] [Related]
2. A single-dose, crossover, placebo- and moxifloxacin-controlled study to assess the effects of neratinib (HKI-272) on cardiac repolarization in healthy adult subjects.
Hug B; Abbas R; Leister C; Burns J; Sonnichsen D
Clin Cancer Res; 2010 Aug; 16(15):4016-23. PubMed ID: 20647478
[TBL] [Abstract][Full Text] [Related]
3. Ascending single-dose study of the safety profile, tolerability, and pharmacokinetics of bosutinib coadministered with ketoconazole to healthy adult subjects.
Abbas R; Leister C; El Gaaloul M; Chalon S; Sonnichsen D
Clin Ther; 2012 Sep; 34(9):2011-9.e1. PubMed ID: 22884766
[TBL] [Abstract][Full Text] [Related]
4. Evaluation of the effect of Naloxegol on cardiac repolarization: a randomized, placebo- and positive-controlled crossover thorough QT/QTc study in healthy volunteers.
Gottfridsson C; Carlson G; Lappalainen J; Sostek M
Clin Ther; 2013 Dec; 35(12):1876-83. PubMed ID: 24238792
[TBL] [Abstract][Full Text] [Related]
5. Effect of single doses of maraviroc on the QT/QTc interval in healthy subjects.
Davis JD; Hackman F; Layton G; Higgins T; Sudworth D; Weissgerber G
Br J Clin Pharmacol; 2008 Apr; 65 Suppl 1(Suppl 1):68-75. PubMed ID: 18333868
[TBL] [Abstract][Full Text] [Related]
6. Ipragliflozin does not prolong QTc interval in healthy male and female subjects: a phase I study.
Zhang W; Smulders R; Abeyratne A; Dietz A; Krauwinkel W; Kadokura T; Keirns J
Clin Ther; 2013 Aug; 35(8):1150-1161.e3. PubMed ID: 23910665
[TBL] [Abstract][Full Text] [Related]
7. Sugammadex is not associated with QT/QTc prolongation: methodology aspects of an intravenous moxifloxacin-controlled thorough QT study.
de Kam PJ; van Kuijk J; Smeets J; Thomsen T; Peeters P
Int J Clin Pharmacol Ther; 2012 Aug; 50(8):595-604. PubMed ID: 22735462
[TBL] [Abstract][Full Text] [Related]
8. A phase I ascending single-dose study of the safety, tolerability, and pharmacokinetics of bosutinib (SKI-606) in healthy adult subjects.
Abbas R; Hug BA; Leister C; Gaaloul ME; Chalon S; Sonnichsen D
Cancer Chemother Pharmacol; 2012 Jan; 69(1):221-7. PubMed ID: 21691746
[TBL] [Abstract][Full Text] [Related]
9. Effects of sugammadex doses up to 32 mg/kg alone or in combination with rocuronium or vecuronium on QTc prolongation: a thorough QTc study.
de Kam PJ; van Kuijk J; Prohn M; Thomsen T; Peeters P
Clin Drug Investig; 2010; 30(9):599-611. PubMed ID: 20568829
[TBL] [Abstract][Full Text] [Related]
10. Thorough QT study of the effects of vildagliptin, a dipeptidyl peptidase IV inhibitor, on cardiac repolarization and conduction in healthy volunteers.
He YL; Zhang Y; Serra D; Wang Y; Ligueros-Saylan M; Dole WP
Curr Med Res Opin; 2011 Jul; 27(7):1453-63. PubMed ID: 21609207
[TBL] [Abstract][Full Text] [Related]
11. Cardiac repolarization with Gabapentin enacarbil in a randomized, double-blind, placebo- and active-controlled, crossover thorough QT/QTc study in healthy adults.
Davy M; Upward J; Arumugham T; Twomey C; Chen C; Stier B
Clin Ther; 2013 Dec; 35(12):1964-74. PubMed ID: 24290737
[TBL] [Abstract][Full Text] [Related]
12. Effect of ketoconazole on the pharmacokinetics of oral bosutinib in healthy subjects.
Abbas R; Hug BA; Leister C; Burns J; Sonnichsen D
J Clin Pharmacol; 2011 Dec; 51(12):1721-7. PubMed ID: 21148045
[TBL] [Abstract][Full Text] [Related]
13. QT effects of duloxetine at supratherapeutic doses: a placebo and positive controlled study.
Zhang L; Chappell J; Gonzales CR; Small D; Knadler MP; Callaghan JT; Francis JL; Desaiah D; Leibowitz M; Ereshefsky L; Hoelscher D; Leese PT; Derby M
J Cardiovasc Pharmacol; 2007 Mar; 49(3):146-53. PubMed ID: 17414226
[TBL] [Abstract][Full Text] [Related]
14. Effect of a single supratherapeutic dose of dolutegravir on cardiac repolarization.
Chen S; Min SS; Peppercorn A; Borland J; Lou Y; Song I; Fujiwara T; Piscitelli SC
Pharmacotherapy; 2012 Apr; 32(4):333-9. PubMed ID: 22422361
[TBL] [Abstract][Full Text] [Related]
15. No effect of a single supratherapeutic dose of lersivirine, a next-generation nonnucleoside reverse transcriptase inhibitor, on corrected QT interval in healthy subjects.
Vourvahis M; Wang R; Ndongo MN; O'Gorman M; Tawadrous M
Antimicrob Agents Chemother; 2012 May; 56(5):2408-13. PubMed ID: 22371898
[TBL] [Abstract][Full Text] [Related]
16. Effects of Therapeutic and Supratherapeutic Doses of Siponimod (BAF312) on Cardiac Repolarization in Healthy Subjects.
Shakeri-Nejad K; Aslanis V; Veldandi UK; Mooney L; Pezous N; Brendani B; Juan A; Allison M; Perry R; Legangneux E
Clin Ther; 2015 Nov; 37(11):2489-2505.e2. PubMed ID: 26519230
[TBL] [Abstract][Full Text] [Related]
17. Effects of a supratherapeutic dose of investigational orally inhaled dihydroergotamine (MAP0004) on QT interval: a randomized, double-blind, active- and placebo-controlled crossover study in healthy volunteers.
Kori S; Kellerman DJ; Voloshko P; Haugen G
Clin Ther; 2012 Sep; 34(9):1920-8. PubMed ID: 22917853
[TBL] [Abstract][Full Text] [Related]
18. Effect of nalmefene 20 and 80 mg on the corrected QT interval and T-wave morphology: a randomized, double-blind, parallel-group, placebo- and moxifloxacin-controlled, single-centre study.
Matz J; Graff C; Vainio PJ; Kallio A; Højer AM; Struijk JJ; Kanters JK; Andersen MP; Toft E
Clin Drug Investig; 2011 Nov; 31(11):799-811. PubMed ID: 21967071
[TBL] [Abstract][Full Text] [Related]
19. Lack of effect of perampanel on QT interval duration: Results from a thorough QT analysis and pooled partial seizure Phase III clinical trials.
Yang H; Laurenza A; Williams B; Patten A; Hussein Z; Ferry J
Epilepsy Res; 2015 Aug; 114():122-30. PubMed ID: 26088895
[TBL] [Abstract][Full Text] [Related]
20. Effects of buprenorphine on QT intervals in healthy subjects: results of 2 randomized positive- and placebo-controlled trials.
Harris SC; Morganroth J; Ripa SR; Thorn MD; Colucci S
Postgrad Med; 2017 Jan; 129(1):69-80. PubMed ID: 27927048
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
